Melanoma

CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma

user February 4, 2021

CV8102 recommended dose identified; expansion trial to confirm safety, tolerability, and efficacy Trial expansion focuses on advanced melanoma, an indication of...

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

Staff June 8, 2024

Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly

Staff June 8, 2024

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

Staff June 8, 2024

Numinus Clarifies Disclosures

Staff June 7, 2024

Woodfords Family Services Media Notice of Information Security Incident

Staff June 7, 2024

error: Content is protected !!

CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma

You may have missed

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

Numinus Clarifies Disclosures

Woodfords Family Services Media Notice of Information Security Incident